Response to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin Lymphoma

Authors

Deepa Jagadeesh
Steve Horwitz
Nancy L Bartlett
Youn Kim
Eric Jacobsen
Madeleine Duvic
Meredith Little
William Trepicchio
Keenan Fenton
Matthew Onsum
Julie Lisano
Ranjana Advani

Publication Date

10-1-2022

Journal

Oncologist

Abstract

BACKGROUND: The safety and efficacy of brentuximab vedotin (BV), an antibody-drug conjugate directed to the CD30 antigen, has been assessed in several trials in patients with peripheral T-cell lymphoma (PTCL), cutaneous T-cell lymphoma (CTCL), or B-cell non-Hodgkin lymphoma (NHL). The objective of this research was to examine the relationship between CD30 expression level and clinical response to BV.

PATIENTS AND METHODS: We analyzed response in patients treated with BV monotherapy in 5 prospective clinical studies in relapsed or refractory PTCL, CTCL, or B-cell NHL. CD30 expression was assessed by immunohistochemistry (IHC) using the Ber H2 antibody for 275 patients.

RESULTS: Across all 5 studies, 140 (50.9%) patients had tumors with CD30 expression

CONCLUSIONS: In this analysis of studies across a range of CD30-expressing lymphomas, CD30 expression alone, as measured by standard IHC, does not predict clinical benefit from BV, making the determination of a threshold level of expression uncertain.

Keywords

Brentuximab Vedotin, Humans, Immunoconjugates, Ki-1 Antigen, Lymphoma, T-Cell, Peripheral, Prospective Studies

Comments

Supplementary Materials.

PMID: 35948003